BOARD OF DIRECTORS
Insmed’s management team is complemented by the stewardship of our Board of Directors. We have assembled a group of individuals who bring impressive business and medical credentials to our company. Together we share the same passion for developing treatments for rare diseases and putting the patient first.
Donald J. Hayden, Jr.
Chairman of the Board
Mr. Hayden has been the non-executive chairman of our board since December 2010, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. He previously served as chairman of the board for Vitae Therapeutics (Nasdaq: VTAE) from 2006 to 2016 until its acquisition by Allergan plc (NYSE: AGN). Mr. Hayden currently serves as chairman of the board of REGENXBIO (Nasdaq: RGNX) as well as director of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden also serves on the board of directors for the privately-held company WindMIL Therapeutics and as a director of Otsuka America Pharmaceutical, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Master of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.
Steinar J. Engelsen, M.D.
Dr. Engelsen has been a member of our board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 2000. Since 1996, Dr. Engelsen has been a partner of Teknoinvest AS, a venture capital firm based in Norway. In addition, from January to November 2000, Dr. Engelsen was acting Chief Executive Officer of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and its affiliated companies. He also served as Senior Vice President, Research and Development of Nycomed Pharma AS from 1994 until 1996. Dr. Engelsen currently serves on the board of Holberg EEG AS, a privately held eHealth company based in Norway. Dr. Engelsen previously served on the board of Capnia Inc. (Nasdaq: CAPN), a medical device company, until December 2017. Dr. Engelsen holds a Master of Science degree in nuclear chemistry and a Doctor of Medicine degree from the University of Oslo and is a Certified European Financial Analyst. Dr. Engelsen is chair of the Nominations & Governance Committee and a member of the Audit Committee.
David W.J. McGirr
Mr. McGirr has been a member of our board since October 2013. From March 2013 to June 2014, Mr. McGirr served as a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that was acquired by Merck and Co. in January 2015. He previously served as Senior Vice President and Chief Financial Officer of Cubist from November 2002 to March 2013, and as Treasurer from 2002 until 2003. From 1999 to 2002, Mr. McGirr was the President and Chief Operating Officer of hippo inc., a venture-financed internet technology company, and was also a member the hippo inc. board of directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB Robins North America, Inc., a risk management company, serving also as Chief Executive Officer from 1997 to 1999. Mr. McGirr was a private equity investor from 1995 to 1996. From 1978 to 1995, Mr. McGirr served in various positions within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg & Co., Inc., a position held from 1992 to 1995. Mr. McGirr served on the board of directors of Relypsa, Inc. from January 2013 until its acquisition by Galencia AG in September 2016, and Roka Bioscience, Inc. from December 2013 until its acquisition by a subsidiary of the Institute for Environmental Health, Inc. in January 2018. Mr. McGirr serves on the board of Rhythm Pharmaceuticals, Inc. (Nasdq: RYTM), Arsanis Inc. (Nasdaq: ASNS), and Menlo Therapeutics (Nasdaq: MNLO), each a clinical-stage biopharmaceutical company. Mr. McGirr holds a Bachelor of Science degree in civil engineering from the University of Glasgow and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania. Mr. McGirr is chair of the Audit Committee.
Alfred F. Altomari
Mr. Altomari was elected to our board in August 2012. Since October 2016, Mr. Altomari has served as chairman of the board and Chief Executive Officer of Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s health specialty pharmaceutical company. Mr. Altomari has been a member of Agile’s board of directors since 2004 and served as President and Chief Executive Officer from 2010 to 2016. Previously, Mr. Altomari served as Agile’s Executive Chairman from 2004 to 2010. From 2008 to September 2010, Mr. Altomari was a consultant to Agile. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier’s board of directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Mr. Altomari also serves on the board of directors of Recro Pharma, Inc. (Nasdaq: REPH). Mr. Altomari holds a Master of Business Administration degree from Rider University and Bachelor of Science degrees in finance and accounting from Drexel University. Mr. Altomari is chair of the Compensation Committee and a member of the Audit Committee.
Mr. Lee has been a member of our board since May 2018. Mr. Lee brings more than 20 years of experience in pharmaceutical innovation, commercialization, regulatory affairs, and policy, and has worked extensively in North America and Asia. Most recently, Mr. Lee served as President, Japan, for Merck KGaA. Prior to his role, he served as President, Japan, for Allergan plc, a global pharmaceutical company, from 2011 to 2015, and as Vice President of Sales at Merck & Co. from 2008 to 2011. From 2003 to 2008, Mr. Lee held various commercial positions at IQVIA (Cegedim Dendrite), a life sciences services company. Mr. Lee also served in various roles at Accelrys, Inc., a software company serving pharmaceutical and biotech companies, from 1997 to 2003. Mr. Lee serves on the board of directors of Regeneus Ltd, a global pharmaceutical company based in Australia. Mr. Lee received a Bachelor of Science in Molecular Genetics and Microbiology from the University of California, Los Angeles.
Ms. Potter has been a member of our board since December 2014. Ms. Potter serves as a director of Rite Aid (NYSE: RAD) and Axsome Therapeutics, Inc. (NYSE: AXSM). Ms. Potter also serves as a director of Liberty Mutual Holding Company, Urovant, and Proteus Digital Health, each a privately held company, and as a trustee of The University of Chicago. She served on the board of Medco Health Solutions from December 2007 until its acquisition by Express Scripts in April 2012 and continued as a director of Express Scripts until June 2012. Ms. Potter served on the board of Everyday Health from 2010 to 2016 until its acquisition by Ziff Davis, LLC. From 2000 to 2005, Ms. Potter was President of Commercial Operations and Chief Operating Officer of Genentech, where she also served as a member of the Executive Committee. At Genentech Ms. Potter led the worldwide commercialization of a robust portfolio, including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™ and TNkase™. Prior to Genentech, she was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic business. Before Bristol-Myers Squibb, Ms. Potter was with Merck & Co. for 14 years where her last position was Vice President of an $800 million U.S. pharmaceutical business unit. Ms. Potter received a Bachelor of Arts degree from The University of Chicago. Ms. Potter is a member of the Compensation Committee.
David R. Brennan
Mr. Brennan joined our board in May 2014, bringing more than 37 years of experience in the pharmaceutical industry. From 2006 to 2012, Mr. Brennan was the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company. Previously at AstraZeneca, Mr. Brennan served as Executive Vice President of North America from 2001 to 2006; and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Mr. Brennan also served as a member of the board of directors of AstraZeneca from 2005 to 2012. Prior to AstraZeneca, Mr. Brennan held various positions at Astra Pharmaceuticals, L.P., Astra Merck, Inc. and Merck and Co. Inc. Mr. Brennan also currently serves as chairman of the board of directors of Alexion Pharmaceuticals (Nasdaq: ALXN) and previously served as Interim CEO from December 2016 to March 2017. Mr. Brennan received a B.A. in Business Administration from Gettysburg College. He is a member of the Compensation Committee.
William H. Lewis, J.D.
President and Chief Executive Officer
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University.
Melvin Sharoky, M.D.
Dr. Sharoky has been a member of our board since May 2001 and served as chairman of our board from June 2009 to December 2010. Since January 2008, Dr. Sharoky has been retired. From 2007 to 2012, he was a member of the board of directors of Par Pharmaceutical Companies, Inc., a publicly-traded pharmaceutical manufacturer, which was subsequently acquired by Endo International plc (Nasdaq: ENDP). From 2002 to 2007, Dr. Sharoky was President and Chief Executive Officer of Somerset Pharmaceuticals, Inc. Dr. Sharoky continued as a consultant to Somerset until 2007. From 2001 to 2002, Dr. Sharoky was retired. From July 1995 to June 2001, Dr. Sharoky served as President of Somerset Pharmaceuticals. From 1995 through 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc. (acquired by Actavis plc), and from 1993 to 1998 he was President and Chief Executive Officer of Watson’s wholly owned subsidiary, Circa Pharmaceuticals, Inc. From 1988 to 1993, Dr. Sharoky held various senior executive positions with Circa Pharmaceuticals. From 1986 to 1988, Dr. Sharoky was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. Dr. Sharoky holds a Bachelor of Arts degree in biology from the University of Maryland in Baltimore County and a Doctor of Medicine degree from the University of Maryland School of Medicine. Dr. Sharoky is a member of the Compensation Committee and the Nominations & Governance Committee.